Serum procalcitonin levels in febrile patients with systemic autoimmune diseases

Current Rheumatology Reviews

Volumn 3, Issue 2, 2007, Pages 103-111

  Trallero Araguás, Ernesto ^a   Selva O'Callaghan, Alberto ^a   Vilardell Tarrés, Miquel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adult Onset Still Disease; ANCA Associated Vasculitis; Calcitonin I (CALC I) gene; Kawasaki disease; Tumour necrosis factor alpha

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; OKT 3; PROCALCITONIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ADULT ONSET STILL DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOMATION; BACTERIAL INFECTION; BEHCET DISEASE; CYTOKINE RELEASE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; FEVER; GRAFT VERSUS HOST REACTION; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PANCREATITIS; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEPSIS; STAPHYLOCOCCUS AUREUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSPORT KINETICS; VASCULITIS; VIRUS INFECTION; WEGENER GRANULOMATOSIS;

EID: 34248638780     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707780619403     Document Type: Review

References (90)

1. Hirsch PF, Lester GE, Talmage RV. Calcitonin, an enigmatic hormone: does it have a function? J Musculoskelet Neuron Interact 200; 1: 299-305.
2. Byfield PG, Turner K, Galante L, et al. The isolation of human calcitonin. Biochem J 1969; 111: 13-14.
3. Becker KL, Nylen ES, Cohen R, Snider RH. Calcitonin: structure, molecular biology, and actions. 1996 In: Bilezikian JP, Raisz LE, Rodan GA, eds. Principles of bone biology. San Diego: Academic Press; 471-494.
4. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984; 167: 93-97.
5. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997; 45: 552-60.
6. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512-25.
7. Gendrel D, Bohuon C. Procalcitonin, a marker of bacterial infection. Infection 1997; 25: 133-34.
8. Nylen ES, Snider RH, Thompson KA, Rohatgi P, Becker KL: Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996; 332: 12-18.
9. Mallet E, Lanse X, Deavaux AM, Ensel P, Basuyau JP, Brunelle P. Hypercalcitoninaemia in fulminant meningococcaemia in children. Lancet 1983; 294.
10. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin - a new indicator of the systemic response to severe infections. Infection 1997; 25: 329-333.
11. Conlon JM, Grimelius L, Thim L. Structural characterization of a high-molecular-mass form of calcitonin [procalcitonin-(60-116)-peptide] and its corresponding N-terminal flanking peptide [procalcitonin-(1-57)-peptide] in a human medullary thyroid carcinoma. Biochem J 1988; 256: 245-250.
12. Silva OL, Broder LE, Doppman JL, et al. Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer 1979; 44: 680-684.
13. Ghillani P, Motte P, Troalen F, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res 1989; 49: 6845-51.
14. Becker KL, Nash D, Silva OL, Snider RH, Moore CF. Increased serum and urinary calcitonin in pulmonary disease. Chest 1981; 79: 211-216.
15. Assicot M, Gendrel D, Carsin H. Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-8.
16. Silva O, Wisneski LA, Cyrus J, Snider RH, Moore CF, Becker KL. Calcitonin in thyroidectomized patients. Am J Med Sci 1978; 275: 159-64.
17. Morgenthaler NG, Struck J, Chancerelle Y, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res 2003; 35: 290-295.
18. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404.
19. Becker KL, Snider RH, Moore CF, Monaghan KG, Silva OL. Calcitonin in extrathyroidal tissues of man. Acta Endocril 1979; 92: 746-751.
20. Bracq S, Machairas M, Clement B, et al. Calcitonin gene expression in normal human liver. FEBS Lett 1993; 331: 155-18.
21. Russwurm S, Stonans L, Stonane E, et al. Procalcitonin and CGRP-1 mRNA expression in various human tissues. Shock 2001; 16: 109-112.
22. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: A novel product of human adipose tissue. Endocrinology 2003; 144: 5578-5584.
23. Oberhoffer K Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134: 49-55.
24. Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expresion in human peripheral blood mononuclead cels and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134: 49-55.
25. Bernard L, Ferriere F, Casassus P, et al. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis 1998; 27: 914-915.
26. Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999; 18: 283-285.
27. Dandona P, Nin D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1974; 79: 1605-8.
28. Chesney RW, McCarron DM, Haddad JG, et al. Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J Lab Clin Med 1983; 101: 576-85.
29. Gendrel D, Raymond J, Assicot M, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997; 24: 1240-1242.
30. Dubos F, Moulin F, Gajdos V, et al. Serum procalcitonin and other biologic markers to distinguish between bacterial and aseptic meningitis. J Pediatr 2006; 149: 72-76.
31. Smith MD, Suputtamongkol Y, Chaowagul W, et al. Elevated serum procalcitonin levels in patients with melioidosis. Clin Infect Dis 1995; 20: 641-5.
32. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323: 17-29.
33. Dèlevaux I, André M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes ? Ann Rheum Dis 2003; 62: 337-340.
34. Schawarz S, Jaccard C, Corradin SB, et al. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000; 28: 1828-1832.
35. Reinhart K, Karzai W, Meisner M. Procalcitoninas a marker of the systemic inflammatory response to infection. Intensive Care Med 2000; 26: 1193-1200.
36. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250-6.
37. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998; 26: 274-6.
38. Scirè CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoinmmune disease. Clin Exp Rheumatol 2006; 24: 123-8.
39. Hollestein U, Looareesuwan S, Aichelburg A, et al. Serum procalcitonin levels in severe Plasmodium falciparum malaria. Am J Trop Med Hyg 1998; 59: 860-863.
40. Baylan O, Balkan A, Inal A, et al. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 2006; 59: 164-167.
41. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21: 939-943.
42. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31: 1737-41.
43. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004; 8: 234-242.
44. Müller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss mod wkly 2001; 131: 595-602.
45. Jensen JU, Heslet L, Jensen TH. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 24: 2596-2602.
46. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in Critically III Patients Admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
47. Gerard Y, Hober D, Assicot M, et al. Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1. J Infect 1997; 35: 41-6.
48. Nylen ES, Whang KT, Snider RH Jr, et al. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001-1006.
49. Becker KL, Nylen ES,, Snider RH, et al. Immunoneutralization of procalcitonin as therapy of sepsis. J Endotoxin Res 2003; 9: 367-374.
50. Wagner KE, Martinez JM, Vath SD, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002; 30: 2313-2321.
51. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
52. Pugin J, Meisner M, Leon A, Gendrel D, Fernandez-Lopez A. (2004). Guide for the clinical use of PCT in diagnosis and monitoring of Sepsis. Retrieved from http://www.procalcitonin.com
53. Meisner M, Lohs T, Huettemann E, et al. The plasma elimination rate and urinary secretion of procalcitoninin patients with normal and impaired renal function. Eur J Anaesthesiol 2001; 18: 79-87.
54. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002; 15: 297-301.
55. Sabat R, Hoflich C, Docke WD, et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 2001; 27: 987-991.
56. Christ-Crain M, Muller B. Procalcitonin - you only find what you look for, and you only look for what you know. J Am Geriat Soc 2006; 54: 546; author reply 547-8.
57. Hubl W, Krassler J, Zingler C, et al. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 2003; 49: 319-27.
58. Meisner M, Brunkhorst FM, Reith HB, Schmidt J, Lestin HG, Reinhart K. Clinical experiences with anew semi-quantitative solid phase immunoassay for rapid measurement of procalcitonin. Clin Chem Lab Med 2000; 38: 989-95.
59. Korczowski B, Malek U, Kowalczyk JR, Rybak A, Zinkiewicz A, Chmielewska A. Two diagnostic assays for serum procalcitonin measurement in clinical practice. Przegl Lek 2003; 60: 345-8.
60. Christ-Crain M, Stolz Daiana, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174: 84-93.
61. Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus crythematosus: a prospective and controlled study of 110 patients. Lupus 2006; 15: 584-589.
62. Bradley JD, Brandt KD, Katz B. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53.
63. Neild GH. Infectious complications in the management of systemic vasculitis and rapidly progressive glomerulonephritis. APMIS Suppl. 1990; 98: 56-60.
64. Cacoub P, Le Thi Huong, Guillevin L, Godeau P. Causes of death in systemic vasculitis of polyarteritis nodosa. Analysis of a series of 165 patients. Ann Med Interne 1988; 139: 381-390.
65. Park KD, Bang D, Lee ES, Lee SH, Lee S. Clinical study on death in Behcet's disease. J Korean Med Sci 1993; 8: 241-5.
66. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 2006; 33: 1740-6.
67. Demina AB, Radenska-Lopovok SG, Folomeeva OM, Erdes Sh. The causes of death of patients with rheumatic diseases in Moscow. Klin Med (Mosk) 2005; 83: 36-43.
68. Christ-Crain M, Müller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swiss med wkly 2005; 135: 451-460.
69. Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998; 25: 1531-3.
70. Kadar J, Petrovicz E. Adult-onset Still's disease. Best Pract Res Clin Rheumatol 2004 ; 18: 663-76.
71. Moosig F, Reinhold-Keller E, Csernok E, Gross WL. Limitations on the usefulness of procalcitonin as a marker of infection in patients with systemic autoimmune disease: comment on the article by Eberhard, et al. Arthritis Rheum. 1998; 41: 556-7; author reply 568.
72. Espinosa-Morales R, Escalante A. Use of procalcitonin as a diagnostic test: comment on the article by Eberhard, et al. Arthritis Rheum. 1998; 41: 567-8.
73. De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 31-38.
74. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004; 31: 2189-98.
75. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001; 19: 329-32.
76. Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004; 48: 199-205.
77. Shin KC, Lee YJ, Kang SW, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 2001; 60: 988-9.
78. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases. Scand J Rheumatol 2003; 32: 2-11.
79. Toivanen P. Normal intestinal microbiotain the aethiopathogenesis of rheumatoid arthritis. Ann Rheum Dis 2003; 62: 807-811.
80. Kuuliala U, Takala A, Siitonen S, Leirisalo-Repo M, Repo H. Cellular and humoral markers of systemic inflammation in acute reactive arthritis and early rheumatoid arthritis. Scand J Rheumatol 2004; 33: 13-18.
81. Adam B, Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet's disease. J Eur Acad Dermatol Venereol 2004; 18: 318-20.
82. Simon L, Gauvin F, Amre DK, Sant-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. CID 2004; 39: 206-17.
83. Hind CRK, NG SC, Feng PH, Pepys MB. Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. Ann Rheum Dis 1985; 44: 260-1.
84. Becker GJ, Waldburger M, Hughes GR, Pepys MB. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980; 39: 50-2.
85. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 156: 1268-73.
86. ter Borg EJ, Horst G, Limburg PC, et al, C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17: 1642-8.
87. Amos RS, Constable TJ, Crockson RA, et al. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977; 1: 195-7.
88. Gross WL. New developments in the treatment of systemic vasculitis. Curr Opin Rheumatol 1994; 6: 11-9.
89. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002; 20: 1-9.
90. Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006; 10: R1.